anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a process for optimizing the recoverability of lyophilized microspheres for emboli and to chitosan microspheres to which a drug-containing carrier is bound. More particularly, the present invention relates to a recoverability optimization process for adding trehalose as a lyophilization protectant prior to a lyophilization for the stable storage of microspheres, and swirling the lyophilized microspheres in order to rehydrate the microspheres. The present invention also relates to microspheres in which the quantity of the drug released from the chitosan microspheres having a drug-containing nanocarrier bound thereto is adjusted based on a drug/chitosan ratio, thus enabling precise drug release adjustment. The present invention also relates to a method for preparing the microspheres. The optimization process of the present invention has the advantages of maintaining the physical properties, shape, and the drug release speed of the microspheres even after the lyophilization of the microspheres for emboli. The chitosan microspheres to which a drug-containing carrier is bound according to the present invention may stably cause emboli in blood vessels, and may precisely adjust the release of a drug and therefore can be used in cancer treatment.
Application of 14C-labeled mupirocin ointment to the lower arm of normal male subjects followed by occlusion for 24 hours showed no measurable systemic absorption (<1.1 nanogram mupirocin per milliliter of whole blood). Measurable radioactivity was present in the stratum corneum of these subjects 72 hours after application. 

Following intravenous or oral administration, mupirocin is rapidly metabolized. The principal metabolite, monic acid, is eliminated by renal excretion, and demonstrates no antibacterial activity. In a trial conducted in 7 healthy adult male subjects, the elimination half-life after intravenous administration of mupirocin was 20 to 40 minutes for mupirocin and 30 to 80 minutes for monic acid. The pharmacokinetics of mupirocin has not been studied in individuals with renal insufficiency.
The invention discloses a lobed kudzuvine root protein tablet. The tablet is prepared from following raw materials by weight: 30-40 parts of lobed kudzuvine root extracts, 13-23 parts of fish-skin collagen, 11-21 parts of corn starch, 2-10 parts of microcrystalline cellulose and 0.25-1 part of magnesium stearate. The raw materials are pressed into the tablet, thus facilitating rapid absorption. The lobed kudzuvine root extracts and the fish-skin collagen are added into the formula of the tablet. According to the medicine food homology theory in traditional Chinese medicine and modern biology theories, the tablet is prepared by modern biotechnology and refined by advanced technology. The tablet is capable of relieving hepatocyte injuries caused by taking medicine, smoking, drinking and excessive pressure for a long time, or caused by being engaged in various poisonous and harmful jobs, and is capable of enhancing liver vitality, and assisting decomposition of toxic substances by the liver.
Embodiments disclosed herein generally relate to multi-arm machine learning models for lesion detection. Particularly, aspects of the present disclosure are directed to accessing a three-dimensional magnetic resonance imaging (MRI) images. Each of the three-dimensional MRI images depict a same volume of a brain of a subject. The volume of the brain includes at least part of one or more lesions. Each three-dimensional MRI image of the three-dimensional MRI images is processed using one or more corresponding encoder arms of a machine-learning model to generate an encoding of the three-dimensional MRI image. The encodings of the three-dimensional MRI images are concatenated to generate a concatenated representation. The concatenated representation is processed using a decoder arm of the machine-learning model to generate a prediction that identifies one or more portions of the volume of the brain predicted to depict at least part of a lesion.
Dental caries and periodontal disease are closely associated with dental plaque, the biofilm that results from microbial colonization of the tooth surface. Various experimental models have been described for the initial phase of colonization, including one that utilizes enamel chips positioned within the oral cavity for periods of time up to 24 hours. Scanning electron microscopy of chips removed after 4 hrs in vivo revealed individual bacteria attached to the pellicle-coated surface. Growth of these pioneer organisms resulted in microcolonies that merged to form a spreading monolayer of cocci and rods. Over 80% of the bacteria present in early biofilms were identified as members of four closely related viridans streptococcal species, Streptococcus sanguis, S. oralis, S. mitis and S. gordonii. Veillonella spp, and Actinomyces naeslundii each composed about 5%. Interestingly, veillonellae, actinomyces and streptococci all increased during the first 24 hrs of colonization thereby suggesting important roles for these bacteria in normal daily plaque accumulation \[early biofilm development\].

One of the major uncertainties raised by the wide-spread ability of cells of oral bacteria to interact physically in vitro is whether these coaggregations function in vivo. Using direct immunofluorescence, we have demonstrated the coincident juxtaposition in dental plaque of streptococci and actinomyces, suggesting that these known coaggregating partners may use coaggregation as a means to colonize enamel. Our overall goal is to determine spatial organization of different viridans streptococci in biofilms that form during initial colonization of the tooth surface. These bacteria include two groups with distinctive properties. One group contains strains of S. sanguis and S. gordonii with GalNAc-sensitive adhesions and the other contains strains of S. oralis and other species with complementary receptors for intrageneric coaggregation. The models for biofilm formation will include an in vitro flow-cell model in which streptococci with known adhesive properties attach and grow on a saliva-coated surface and an in vivo model in which enamel chips are colonized within the oral cavity for periods of time up to 72 hours. The results of these studies should provide significant insights into the involvement of interbacterial adhesion in biofilm development. Our goal from these studies is to investigate the spatial organization of streptococci and their coaggregation partner actinomyces and veillonellae in biofilms formed in vivo compared to in vitro. We hope to make significant advances in understanding the distribution of these species in initial dental plaque formation. Since the streptococci are the predominant organism in early dental plaque, we propose that understanding their contribution to microbial communities will lead to important advances in designing effective oral health regimens.
The purpose of the proposed study is to test the real-world effectiveness of the ReACH (Reducing Alcohol use and related Comorbidities in HIV care) telehealth counseling protocol in a pragmatic Hybrid Type 1 effectiveness-implementation randomized trial. The study will recruit 600 heavy-drinking PLWH from four federally-qualified health centers in geographically distinct regions across the U.S, which provide services to over 14,000 PLWH. Upon completing enrollment, participants will be randomized to receive either single-session brief intervention (BI) by phone with referral to local treatment when appropriate or BI plus referral to ReACH telehealth counseling (TC). Participants will complete follow-ups through 24 months after baseline to assess longer-term changes in drinking and health outcomes. The study will test the hypothesis that TC compared to BI will result in (a) reduced number of drinks consumed per week and frequency of heavy drinking and (b) increased odds of having an undetectable viral load at 12- and 24-month follow-ups. Secondary outcomes include self-reported ART adherence, engagement in condomless sex with non-exclusive partners, frequency of other substance use, phosphatidylethanol levels (a biomarker of recent alcohol use), and Veterans Aging Cohort Study index scores. The study also will examine potential moderators of TC effectiveness. As a secondary aim, implementation measures corresponding to aspects of the Dynamic Sustainability Framework will be assessed including implementation outcomes of acceptability, appropriateness, and feasibility guided by Proctor's Implementation Outcomes Framework. Thus, this pragmatic Hybrid Type 1 trial will help establish the real-world effectiveness of the ReACH TC intervention while also providing key implementation-related measures and outcomes that will inform future ReACH TC scale up and sustainability.
Certain diterpenes as well as extracts or concentrates of the plant  Curcuma amada  containing at least one such diterpene can be used as medicaments for immunomodulation and for the alleviation of pain. Specifically, they are used for preparing medicaments for the treatment or prevention of hypersensitivity diseases, in particular IgE mediated allergic reactions and conditions as well as autoimmune disorders. Extracts of the plant can i.e. be obtained by extraction or by hydro, steam or vacuum distillation of fresh or dried  Curcuma amada  or parts thereof, preferably the rhizome. Extraction may be performed with water or with a number of different organic solvents, preferably water miscible solvents, or with mixtures thereof. After the primary distillation or extraction process a second step of processing, such as liquid-liquid extraction, column chromatography, steam distillation or vacuum distillation, can be employed to remove or to concentrate and possibly isolate any constituent of the extract.
Patients receive abiraterone acetate orally PO QD or enzalutamide PO QD on days 1-21. Patients also receive erdafitinib PO QD on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
Long non-coding RNAs (lncRNAs) have been implicated in dilated cardiomyopathy (DCM). However, the biological functions and regulatory mechanisms of lncRNAs in DCM remain elusive. Using a mouse model of experimental autoimmune myocarditis (EAM) to mimic DCM, we successfully constructed a dynamic lncRNA expression library for EAM by lncRNA microarray and found that the expression of a macrophage-enriched lncRNA, MAAMT, was significantly increased in the myocardial tissue of mice at the acute stage of EAM. Functionally, MAAMT knockdown alleviated the recruitment and proinflammatory activation of macrophages in the heart, spleen, and peripheral blood of mice at the acute stage of EAM, reduced myocardial inflammation and injury, and eventually reversed ventricular remodelling and improved cardiac function in mice at the chronic stage of EAM. Mechanistically, we identified serine/arginine-rich splicing factor 1 (SRSF1) as an MAAMT-interacting protein in macrophages using RNA pull-down assays coupled with mass spectrometry. MAAMT knockdown attenuated the ubiquitination-mediated degradation of SRSF1, increased the protein expression of SRSF1, and restrained the activation of the NF-κB pathway in macrophages, thereby inhibiting the proinflammatory activation of macrophages. Collectively, our results demonstrate that MAAMT is a key proinflammatory regulator of myocarditis that promotes macrophage activation through the SRSF1-NF-κB axis, providing a new insight into early effective treatment strategies for DCM.
Dietary supplements enriched with bioactive compounds represent a promising approach to influence physiological processes and enhance longevity and overall health. Cynara cardunculus var. scolymus serves as a functional food supplement with a high concentration of bioactive compounds, which offers various health-promoting benefits. Several chronic diseases have metabolic, genetic, or inflammatory origins, which are frequently interconnected. Pharmacological treatments, although effective, often result in undesirable side effects. In this context, preventive approaches are gaining increased attention. Recent literature indicates that the consumption of bioactive compounds in the diet can positively influence the organism's biological functions. Polyphenols, well-known for their health benefits, are widely recognized as valuable compounds in preventing/combating various pathologies related to lifestyle, metabolism, and aging. The C. scolymus belonging to the Asteraceae family, is widely used in the food and herbal medicine fields for its beneficial properties. Although the inflorescences (capitula) of the artichoke are used for food and culinary purposes, preparations based on artichoke leaves can be used as an active ingredient in herbal medicines. Cynara scolymus shows potential benefits in different domains. Its nutritional value and health benefits make it a promising candidate for improving overall well-being. C. scolymus exhibits anti-inflammatory, antioxidant, liver-protective, bile-expelling, antimicrobial, and lipid-lowering neuroprotective properties. Different studies demonstrate that oxidative stress is the leading cause of the onset and progression of major human health disorders such as cardiovascular, neurological, metabolic, and cancer diseases. The large amount of polyphenol found in C. scolymus has an antioxidant activity, enabling it to neutralize free radicals, preventing cellular damage. This reduces the subsequent risk of developing conditions such as cancer, diabetes, and cardiovascular diseases. Additionally, these polyphenols demonstrate anti-inflammatory activity, which is closely associated with their antioxidant properties. As a result, C. scolymus has the potential to contribute to the treatment of chronic diseases, including intestinal disorders, cardiovascular diseases, and neurodegenerative pathologies. The current review discussed the nutritional profiles, potential benefits, and pharmacological effects of C. scolymus.
In this prospective randomized trial, male patients with a primary symptomatic unilateral inguinal hernia will be admitted to the trial. All patients must be over 21 years of age. In order to avoid inguinal nerve entrapment or damage by mesh fixation sutures Covidien Parietene ProGrip mesh will be employed. This mesh does not require fixation. Standard open inguinal hernia repair will take place with nerve preservation, as day surgery cases. In the randomized portion of the study, the mesh will be placed as usual along the posterior wall of the inguinal canal, however the inguinal ligament will be interposed between the mesh and the spermatic cord, thus isolating the cord from intimate contact with the mesh, and a reduction in postoperative inflammatory changes.
BACKGROUND: The treatment of end-stage chronic renal failure involves substantial costs for health care, which could be higher considering hemodialysis access complications management costs. Complications could be addressed by cannulation technique, but also by the needle. In particular, the use of a metal needle for cannulation is responsible for several complications that compromise dialysis delivery and require interventions. This analysis aims to evaluate, from a hospital perspective, the direct costs related to complications that may occur in hemodialysis patients in Italy.
METHODS: To identify the main complications to consider in our analysis and related patient pathway for their management, we conducted an international literature search on PubMed and validated the data for Italy with an Italian Key Opinion Leader (KOL). A micro-costing analysis was developed to precisely assess the economic costs of healthcare interventions to manage complications due to vascular access cannulation.
RESULTS: The major complications identified, and the average cost/per episode for their management are the following ones: Local infection € 1455 (min € 745 and max € 2160); Sepsis, that requires hospitalization in ward € 4401 (min € 3693 and max € 4623); Sepsis (ICU) € 17,190; Hematoma € 304 (min € 252 and max € 728); Aneurysm € 3632 (min € 3139 and max € 4014); Pseudoaneurysm € 3695 (min € 3615 and max € 4014); Stenosis € 2229 (min € 1874 and max € 4857); Thrombosis € 2151 (min € 1941 and max € 3395).
CONCLUSIONS: In making decisions, hospital administration, and payer should take into consideration, not just the price of devices, but the entire patient's pathway. The use of plastic cannulae in hemodialysis patients shows improved outcomes compared to traditional metal needles. Furthermore, combining it with accurate and efficient cannulation techniques reduces complication rates, improves patients' quality of life, and reduces healthcare resource consumption.
In a dimly lit room the participant will place their chin on the slit lamp We will use t he optimal background illumination used for Humphrey and Goldman visual fields which is 31.5 apostilbs (10Lux 9 They will look into the video camera placed 50cm away, which will have a dimmable remote control ring light fitted around it. The part icipant will have a reference measure taped to the headrest and three electrodes placed around the right eye. One active electrode place on the lower lid and one reference electrode towards the temporal margin and one earth electrode placed on the forehead The brightness of the ring light will be increased via the dimmer switch whilst simultaneously recording the lux with the LED light meter. The participant will be advised t o close their eyes if the brightness becomes uncomfortable and this will be repea ted three times.
A novel synergistic pharmaceutical composition for preparation of topical formulations for prophylaxis and treatment of wounds, burn wounds, skin grafts, pressure ulcers and diabetic foot ulcers is disclosed. The synergistic composition comprises a mitogenic protein in combination with one or more bactericidal and bacteriostatic agents. The mitogenic protein in the invention is Recombinant Human Epidermal Growth Factor (rh-EGF of Bharat Biotech International Limited) and /or any other growth factor like rh-PDGF-BB and the bactericidal and bacteriostatic agents are broad spectrum antibiotics silver sulfadiazine (SSD) and chlorhexidine glucomate (CHG). The topical formulations, in addition to the synergistic composition, also comprise base ingredients, carriers, preservatives, emulsifiers, skin. emollients and soothers and one or more other constituents. The novel composition results in synergistic effects like broader antibacterial coverage, reversal of silver effect of SSD by rh-EGF, effectiveness against silver resistant microorganisms in burn wounds, and better and faster wound healing. The novel composition may be used to prepare the topical formulations in the form of cream, gel or liquid. The novel formulations have longer shelf life and are stable for more than two years at the storage temperature of 2-8° degrees.
Disclosed herein is a system and method for producing T cells from stem cell populations. Specifically exemplified herein is a culture system and method that produces CD4 cells and/or T cell subtypes from a CD4 lineage using a sample of hematopoietic stem cells. Adult hematopoietic precursor/stem cells (HPC) are progenitors to all lineages of immune cells. There has been limited success in generating functional CD4 T cells with this convenient culture system. Also disclosed herein is a novel stromal cell line expressing DL1, interleukin-7 (IL-7), and FMS-like tyrosine kinase 3 ligand (Flt3-L). This improved culture system can greatly facilitate the study of late T cell development and enables immunotherapeutic applications.
Multi-patient monitor. The present invention concerns a multi-patient monitoring system intended to collect vital signs data for more than one patient at the same time. All the patients are connecting to a central station that organizes the transitions between them. The transition between patients is frequently with a timer predefined by the physician, if any complication occur for a patient the transition is blocked and only his data displayed. This system is indicated in particular the case of a health crisis where the number of patient deposes the number of available patient monitor. In addition the new system used in the normal state but in order to improve the public health condition and to present more care services.
PROBLEM TO BE SOLVED: To provide a material usable as a transplant piece in an organism and functioning as a substitute for bone tissue by comprising a macro pore having a size of the range of a specified value and a micro pore having a size of the range of a specified value. SOLUTION: This bone inductive biocompatible material is produced by sintering a ceramic material under a condition as provides the bone inductive living body compatible material. The bone inductive biocompatible material comprises both macro pores and micro pores, and the total porosity is 20-90%. The macro pore has a size of 0.1-1.5 mm. The preferable size of the macro pore is within the range of 0.2-1 mm. The size of the macro pore has a remarkably useful influence on the bone inducing characteristic of this material. The micro pore has a size of 0.05-20 μm. The preferable size of the micro pore is within the range of 0.5-10 μm. In this range, the micro pore is present at least on the surface of the macro pore.
This arm, undergoing the "68-Gallium citrate PET/CT scan intervention", includes the PET/CT scans performed with 68Gallium-citrate radiotracer. Note that same patients scanned with different radiotracers serve in both arms.
Ribavirin demonstrated significant embryocidal and/or teratogenic effects at doses well below the recommended human dose in all animal species in which adequate studies have been conducted.

Fertile women and partners of fertile women should not receive ribavirin unless the patient and his/her partner are using effective contraception (two reliable forms). Based on a multiple dose half-life(t1/2) of ribavirin of 12 days, effective contraception must be utilized for 6 months posttherapy (e.g., 15 half-lives of clearance for ribavirin).

Ribavirin should be used with caution in fertile men. In studies in mice to evaluate the time course and reversibility of ribavirin-induced testicular degeneration at doses of 15 to 150 mg/kg/day (estimated human equivalent of 1.25 to 12.5 mg/kg/day, based on body surface area adjustment for a 60 kg adult; 0.1 to 0.8 times the maximum human 24-hour dose of ribavirin) administered for 3 or 6 months, abnormalities in sperm occurred. Upon cessation of treatment, essentially total recovery from ribavirin-induced testicular toxicity was apparent within 1 or 2 spermatogenesis cycles.
Richter's syndrome (RS) is the transformation of chronic lymphocytic leukemia (CLL) into a high-grade B-cell malignancy. Molecular and functional studies have pointed out that CLL cells are close to the apoptotic threshold and dependent on BCL-2 for survival. However, it remains undefined how evasion from apoptosis evolves during disease transformation. Here, we employed functional and static approaches to compare the regulation of mitochondrial apoptosis in CLL and RS. BH3 profiling of 17 CLL and 9 RS samples demonstrated that RS cells had reduced apoptotic priming and lower BCL-2 dependence than CLL cells. While a subset of RS was dependent on alternative anti-apoptotic proteins and was sensitive to specific BH3 mimetics, other RS cases harbored no specific anti-apoptotic addiction. Transcriptomics of paired CLL/RS samples revealed downregulation of pro-apoptotic sensitizers during disease transformation. Albeit expressed, effector and activator members were less likely to colocalize with mitochondria in RS compared to CLL. Electron microscopy highlighted reduced cristae width in RS mitochondria, a condition further promoting apoptosis resistance. Collectively, our data suggest that RS cells evolve multiple mechanisms that lower the apoptotic priming and shift the anti-apoptotic dependencies away from BCL-2, making direct targeting of mitochondrial apoptosis more challenging after disease transformation.